1. Home
  2. ATNI vs ZVRA Comparison

ATNI vs ZVRA Comparison

Compare ATNI & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ATN International Inc.

ATNI

ATN International Inc.

HOLD

Current Price

$31.99

Market Cap

482.0M

ML Signal

HOLD

Logo Zevra Therapeutics Inc.

ZVRA

Zevra Therapeutics Inc.

HOLD

Current Price

$12.10

Market Cap

562.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ATNI
ZVRA
Founded
1987
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
482.0M
562.2M
IPO Year
1994
2015

Fundamental Metrics

Financial Performance
Metric
ATNI
ZVRA
Price
$31.99
$12.10
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$23.00
AVG Volume (30 Days)
75.8K
1.4M
Earning Date
05-06-2026
05-06-2026
Dividend Yield
4.03%
N/A
EPS Growth
34.29
159.21
EPS
10.44
0.74
Revenue
$727,975,000.00
$106,470,000.00
Revenue This Year
$3.12
$37.27
Revenue Next Year
$1.10
$53.42
P/E Ratio
$3.05
$16.39
Revenue Growth
N/A
350.91
52 Week Low
$13.86
$7.16
52 Week High
$33.41
$15.04

Technical Indicators

Market Signals
Indicator
ATNI
ZVRA
Relative Strength Index (RSI) 70.55 56.05
Support Level $25.03 $8.26
Resistance Level $33.41 $12.19
Average True Range (ATR) 1.36 0.46
MACD 0.46 0.19
Stochastic Oscillator 85.21 89.43

Price Performance

Historical Comparison
ATNI
ZVRA

About ATNI ATN International Inc.

ATN International Inc is a telecommunications and utilities company. The company provides digital infrastructure and communications services with a focus on rural and remote markets in the United States, and internationally, including Bermuda and the Caribbean region. Its operating segments comprise U.S. Telecom and International Telecom. The company earns revenue from its International telecommunication segment.

About ZVRA Zevra Therapeutics Inc.

Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.

Share on Social Networks: